Çalışma Alanları
- Sağlık Bilimleri Temel Alanı
- Hematoloji (İç Hastalıkları)
- In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT, 2024
- Germline genetic variants in Turkish familial multiple myeloma/monoclonal gammopathy of undetermined significance cases, 2024
- Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG), 2024
- Current barriers and recommendations on the diagnosis of transthyretin amyloid cardiomyopathy: a Delphi study, 2024
- Transcriptome analysis of beta-catenin-related genes in CD34+ haematopoietic stem and progenitor cells from patients with AML, 2024
- A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma, 2024
- Current Landscape of iPSC Haplobanks, 2024
- A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma, 2024
- Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)., 2024
- Isatuximab-pomalidomide-dexamethasone <i>versus</i> pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis, 2024
- Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma: A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment, 2024
- In vivo and in vitro effects of cord blood hematopoietic stem and progenitor cell (HSPC) expansion using valproic acid and/or nicotinamide, 2024
- Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison, 2024
- Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma, 2024
- Inhibition of O6‐methylguanine‐DNA‐methyltransferase (MGMT) by lomeguatrib reduces multiple myeloma cell viability and impairs DNA repair in MGMT‐proficient cells, 2024
- Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients, 2024
- Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group, 2023
- Stem cell mobilizating effect of heparin in patients undergoing autologous stem cell transplantation, 2023
- Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT, 2023
- Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center, 2023
- Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network, 2023
- Upfront autologous transplantation still improving outcomes in patients with multiple myeloma, 2023
- Generic Lenalidomide Rivelime Versus Brand-name Revlimid® in the Treatment of Relapsed/Refractory Multiple Myeloma: A Retrospective Single-center Experience on Efficacy, Safety and Survival Outcome, 2023
- Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP‐EBMT study, 2023
- HIV‐1 integrase inhibitor raltegravir promotes DNA damage‐induced apoptosis in multiple myeloma, 2023
- An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT, 2023
- A Novel Hypothesis: Certain KIR/Cognate Ligand Containing Genotypes Differ in Frequency Among Patients With Myeloma and Have an Effect on Age of Disease Onset, 2023
- Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data, 2023
- Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT, 2023
- Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial, 2023
- Werner helicase is required for proliferation and DNA damage repair in multiple myeloma, 2022
- Upfront autologous transplantation still improving outcomes in patients with multiple myeloma, 2022
- First Experience of 11C-Methionine PET in Multiple Myeloma in Turkey, 2022
- ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma, 2022
- Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper, 2022
- Is Quantification of Measurable Clonal Plasma Cells in Stem Cell Grafts (gMRD) Clinically Meaningful?, 2022
- Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma, 2022
- Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA, 2022
- Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial, 2022
- Manual Versus Automated Volume Reduction of Cord Blood, 2022
- Autologous hematopoietic cell transplantation for relapsed multiple myeloma performed with cells procured after previous transplantation–study on behalf of CMWP of the EBMT, 2022
- Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT, 2022
- Ex vivo expansion of natural killer cells for hematological cancer immunotherapy: a systematic review and meta-analysis, 2022
- The efficacy and safety of second allogeneic hematopoietic stem cell transplantation., 2022
- Pretransplant Consolidation Therapies Improve the Outcome of Myeloablative Allogeneic Transplantation in Adults with Ph-negative Acute Lymphoblastic Leukemia, 2022
- Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies, 2022
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study, 2022
- Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics, 2022
- Health\u2010related quality of life in patients with\n <scp>light chain<\/scp>\n amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone\u2009±\u2009daratumumab: Results from the\n <scp>ANDROMEDA<\/scp>\n study, 2022
- Extramedullary disease in multiple myeloma: a systematic literature review, 2022
- Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019, 2022
- Alpha-1-Antitrypsin Experience for Steroid-Resistant Acute Graft-Versus-Host Disease, 2022
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study, 2022
- A model integrating Killer Immunoglobulin-like Receptor (KIR) haplotypes for risk prediction of COVID-19 clinical disease severity, 2021
- Highlighting the Prognostic Importance of Measurable Residual Disease Amongst Acute Myeloid Leukemia Risk Factors, 2021
- A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome, 2021
- Post-Transplantation Cyclophosphamide for Graft-versus- Host Disease Prophylaxis in Multiple Myeloma Patients Who Underwent Allogeneic Hematopoietic Cell Transplantation: First Comparison by Donor Type. A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, 2021
- Significance of inhibitory maternal killer-cell immunoglobulin-like receptor (KIR) and fetal KIR ligand genotype combinations in placenta related obstetric complications, 2021
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study, 2021
- Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study, 2021
- Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma, 2021
- Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT), 2021
- Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis, 2021
- COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network, 2021
- Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma, 2021
- Bone Marrow Microenvironment Interplay and Current Clinical Practice in Multiple Myeloma: A Review of the Balkan Myeloma Study Group, 2021
- Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide\u2010pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics, 2021
- Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network, 2021
- Pleural Involvement Upon Relapse of Myeloma Responding to Daratumumab Plus Carfilzomib: A Case Presentation and Literature Review, 2021
- Health\u2010related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial, 2021
- Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party, 2021
- Expert review on soft\u2010tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations, 2021
- A Rare Extramedullary Presentation of Multiple Myeloma: Paraspinal Muscle Involvement Revealed by FDG PET/CT, 2021
- Prognostic impact of early\u2010versus\u2010late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT, 2021
- HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA, 2021
- Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study, 2021
- Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group, 2021
- Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma, 2021
- Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial, 2021
- CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma, 2021
- Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors, 2021
- Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation, 2020
- A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome., 2020
- A Rare Extramedullary Presentation of Multiple Myeloma: Paraspinal Muscle Involvement Revealed by FDG-PET/CT, 2020
- Allogeneic hematopoietic stem cell transplantation for primary myelofibrosis: A single-center experience., 2020
- β-catenin mutations in acute myeloid leukemia, 2020
- β-catenin mutations in acute myeloid leukemia, 2020
- Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk, 2020
- Efficacy and safety of weekly carfilzomib (70 mg/m sup2/sup ), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies/title, 2020
- Efficacy and safety of weekly carfilzomib (70\u2009mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies, 2020
- Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM), 2020
- Allogeneic hematopoietic cell transplantation (allo-HCT) outcomes in myeloma patients on renal replacement therapy: a report from the Chronic Malignancy Working Party (CMWP) of the European Society of Blood and Marrow Transplantation (EBMT), 2020
- β-catenin mutations in acute myeloid leukemia, 2020
- Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk, 2020
- Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network, 2020
- β-catenin mutations in acute myeloid leukemia, 2020
- Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data, 2020
- Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set, 2020
- Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk, 2020
- Drug Targeting of Genomic Instability in Multiple Myeloma, 2020
- Isatuximab for the treatment of relapsed/refractory multiple myeloma, 2020
- Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study, 2020
- Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial, 2020
- Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study, 2020
- Fetal Cell Microchimerism Normal and Immunocompromised Gestations in Mice, 2020
- Prognostic scoring system after transplantation in myeloma: predicting early relapse, 2020
- Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network, 2020
- Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma, 2020
- Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma, 2020
- Thyroid dysfunctions in adult patients after allogeneic hematopoietic stem cell transplantation, 2020
- Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study, 2020
- Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS), 2020
- Are Autologous Stem Cell Transplants Still Required to Treat Myeloma in the Era of Novel Therapies? A Review from the Chronic Malignancies Working Party of the EBMT, 2020
- Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma, 2020
- Our Treatment Approach to Hairy Cell Leukemia, 2020
- Determination of the Apoptotic Effect and Molecular Docking of Benzamide Derivative XT5 in K562 Cells, 2019
- A comparative safety review of histone deacetylase inhibitors for the treatment of myeloma, 2019
- PET with Fluorodeoxyglucose F 18/Computed Tomography as a Staging Tool in Multiple Myeloma, 2019
- A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome, 2019
- Insights on Multiple Myeloma Treatment Strategies, 2019
- Natural Killer Cell-Mediated Cellular Therapy of Hematological Malignancies, 2019
- Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial, 2019
- Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial, 2019
- A comparison of the efficacy of immunomodulatory-free regimens in relapsed or refractory multiple myeloma: a network meta-analysis, 2019
- Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients, 2019
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study, 2019
- Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Lenalidomide and/or Bortezomib Containing Regimens, 2019
- Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019, 2019
- Fetal Cell Microchimerism Normal and Immunocompromised Gestations in Mice, 2019
- Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma, 2019
- Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience af a Single Center, 2018
- Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience af a Single Center, 2018
- The outcome of Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation for Isolated CD4T cell Deficiency with Interleukin-2 Inducible T-cell Kinase (ITK) Gene Defect, 2018
- The impact of 17 B estradiol level variations on blood lymphocyte counts among healthy females, 2018
- Factors influencing the success of cord blood collection: a tertiary perinatal medicine center’s experience, 2018
- title Daratumumab plus bortezomib and dexamethasone iversus/i bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR/title, 2018
- Factors influencing the success of cord blood collection: a tertiary perinatal medicine center’s experience, 2018
- The Impact of 17Β Estradiol Level Variations on Blood Lymphocyte Counts Among Healthy Females, 2018
- Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies, 2018
- KRONİK LENFOSİTİK LÖSEMİ’DE TANI ANINDA HİPOGAMMAGLOBULİNEMİ SAĞKALIM VE ENFEKSİYON RİSKİ ÜZERİNDE ETKİLİ MİDİR?, 2018
- KRONİK LENFOSİTİK LÖSEMİ’DE TANI ANINDA HİPOGAMMAGLOBULİNEMİ SAĞKALIM VE ENFEKSİYON RİSKİ ÜZERİNDE ETKİLİ MİDİR?, 2018
- Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?, 2018
- Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation, 2018
- Kronik Lenfositik Lösemi’de Tanı Anında Hipogammaglobulinemi Sağkalım ve Enfeksiyon Riski Üzerine Etklili Midir?, 2018
- Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients., 2018
- Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?, 2018
- Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study, 2018
- A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis, 2018
- The Impact of 17Β Estradiol Level Variations on Blood Lymphocyte Counts Among Healthy Females, 2018
- Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies, 2018
- Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipientss?, 2018
- Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study, 2018
- Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?, 2018
- Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?, 2018
- Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?, 2018
- The safety of bortezomib for the treatment of multiple myeloma, 2018
- Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network, 2018
- Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel, 2018
- Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?, 2018
- Total Blood Lymphocyte Count Alteration During and after Pregnancy, 2017
- Subsequent malignancies after allogeneic hematopoietic stem cell transplantation, 2017
- Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma, 2017
- Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study, 2017
- Flow Cytometric Aldehyde Dehydrogenase Assay Enables a Fast and Accurate Human Umbilical Cord Blood Hematopoietic Stem Cell Assessment, 2017
- Extracorporeal photochemotherapy in mycosis fungoides, 2017
- Heparin enhances CD34 content of stem cells collected following G-CSF /- chemotherapy, 2017
- Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study, 2017
- Determination of the apoptotic effect and molecular docking of benzamide derivative XT5 in K562 cells, 2017
- Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study, 2017
- Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and ipost-hoc/i analyses on progression-free survival and tumour growth/title, 2017
- Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study, 2017
- Allogeneic Transplantation In Chronic Myeloid Leukemia And The Effect Of Tyrosine Kinase Inhibitors On Survival, A Quasi-Experimental Study, 2017
- A single center experience with two decades of follow-up on patients with hairy cell leukemia., 2017
- Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantations for acute myeloid leukemia., 2017
- A single center experience with two decades of follow-up on patients with hairy cell leukemia., 2017
- Large unstained cell percentage as a predictor ofefficacious peripheral stem cell mobilization in autologousstem cell transplantation, 2017
- Evaluating peritransplant albumin decline as a predictor ofacute graft versus host disease, 2017
- Allogeneic hematopoietic stem cell transplantation(allo-HSCT) in advanced age adults: is it possible totransplant safely?, 2017
- P529HLA C1/C1 homozygosity decreases relapse rate afterallogeneic hematopoietic stem cell transplantation(Allo-HSCT) in acute myeloid leukemia (AML) patients, 2017
- A Biosimiliar G-CSF filgrastim is as effective as a referencedrug however itis not as cost effectiveas it supposed to beand by the way no impact on the health care system, 2017
- Peripheral blood stem cell mobilization and collectionfrom elderly patients (≥65 years) with multiple myeloma: Asingle center experience, 2017
- Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study, 2017
- Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial, 2017
- THE IMPACT OF 17Β ESTRADIOL LEVEL VARIATIONS ON BLOOD LYMPHOCYTE COUNTS AMONG HEALTHY FEMALES, 2017
- extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft versus host disease, 2017
- A Case of Superwarfarin Poisoning Due to Repetitive Occupational Dermal Rodenticide Exposure in a Worker, 2016
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma, 2016
- Two phase 3 studies of the oral proteasome inhibitor (PI) ixazomib for multiple myeloma (MM) in the maintenance setting: TOURMALINE-MM3, and -MM4., 2016
- Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial), 2016
- Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial)., 2016
- Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study., 2016
- Consolidation Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Study of the European Myeloma Network (EMN02/HO95 MM Trial), 2016
- Is There Any Reason to Prefer Cord Blood Instead of Adult Donors for Hematopoietic Stem Cell Transplants, 2016
- How to Improve Cord Blood Engraftment, 2016
- Editorial How to Improve Cord Blood Transplantation By Enhancing Cell Counts or Engraftment, 2016
- Flow Cytometrıc Aldehyde Dehydrogenase Aldh Assay Enables A Fast And Accurate Human Umblical Cord Blood Hematopoietic Stem Cell Assessment, 2016
- Phase 2 study of tabalumab a human anti B cell activating factor antibody with bortezomib and dexamethasone in patients with previously treated multiple myeloma, 2016
- Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone the PANORAMA 1 trial a randomised placebo controlled phase 3 trial, 2016
- HLA polymorphism and risk of multiple myeloma, 2016
- Daratumumab Bortezomib and Dexamethasone for Multiple Myeloma, 2016
- Central nervous system involvement by multiple myeloma A multi institutional retrospective study of 172 patients in daily clinical practice, 2016
- Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma outcomes by prior treatment, 2016
- A Case of Superwarfarin Poisoning Due to Repetitive Occupational Dermal Rodenticide Exposure in a Worker, 2016
- Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation, 2015
- Does Low-Molecular-Weight Heparin Influence the Antimyeloma Effects of Thalidomide? A Retrospective Analysis of Data from the GIMEMA, Nordic and Turkish Myeloma Study Groups, 2015
- Effects of in utero cord blood collection on post-cesarean hemoglobin levels, 2015
- Impact of “Killer Immunoglobulin-Like Receptor /Ligand” Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival, 2015
- European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications, 2015
- Insight into human protease activated receptor-1 as anticancer target by molecular modelling, 2015
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma, 2015
- Panobinostat a novel pan deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma, 2015
- Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma results from the EBMT NMAM2000 prospective trial, 2015
- Antilymphocyte Thymocyte Globulin for the Treatment of Steroid Refractory Acute Graft Versus Host Disease 20 Year Experience at a Single Center, 2015
- Analysis of Final Data from the Multinational Non Interventional Observational Emmos Study NCT01241396 in Patients Pts with Multiple Myeloma MM in Real World Clinical Practice, 2015
- Retrospective matched pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma, 2015
- Impact of PET-CT Response on Survival Parameters Following Autologous Stem Cell Transplantation Among Patients with Multiple Myeloma: Comparison of Two Cut-Off Values, 2014
- Management of Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation, 2014
- European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma, 2014
- High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial, 2014
- Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study, 2014
- Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee, 2014
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial, 2014
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, 2014
- Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma, 2014
- HLA typing with sequence-specific oligonucleotide primed PCR (PCR-SSO) and use of the Luminex™ technology, 2014
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma a multicentre randomised double blind phase 3 trial, 2014
- Hemorrhagic Cystitis as a Complication of Bone Marrow Transplantation, 2013
- Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma, 2013
- Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study, 2013
- Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease, 2013
- Flowcytometric evaluation of cell cycle regulators (cyclins and cyclin dependent kinase inhibitors) expressed on bone marrow cells of patients with chronic myelogenous leukemia and multiple myeloma, 2012
- Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients, 2012
- Regional differences in the treatment approaches for relapsed multiple myeloma: An IMF study., 2012
- IMWG consensus on maintenance therapy in multiple myeloma, 2012
- Management of treatment-emergent peripheral neuropathy in multiple myeloma, 2012
- Stem Cell Therapy in Spinal Cord Injury: In Vivo and Postmortem Tracking of Bone Marrow Mononuclear or Mesenchymal Stem Cells, 2012
- Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials, 2012
- Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma, 2012
- Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective, 2011
- Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up, 2011
- Short and long term effects of granulocyte colony-stimulating factor during induction therapy in acute myeloid leukemia patients younger than 65: Results of a randomized multicenter phase III trial, 2011
- An attempt to treat patients who have injured spinal cords with intralesional implantation of concentrated autologous bone marrow cells, 2011
- Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement, 2011
- Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group, 2011
- Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN), 2011
- Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials, 2011
- The Shaping of Modern Human Immune Systems by Multiregional Admixture with Archaic Humans, 2011
- Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3, 2011
- Is it time to revisit our current hematopoietic progenitor cell quantification methods in the clinic?, 2011
- Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective, 2010
- Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial, 2010
- Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations, 2010
- Lack of Prognostic Value of CD34 in Adult AML, 2009
- Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF, 2009
- Bone Marrow Microvessel Density (MVD) in Adult Acute Myeloid Leukemia (AML): Therapy Induced Changes and Effects on Survival, 2009
- International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma, 2009
- Vitiligo after Hematopoietic Cell Transplantation: Six Cases and Review of the Literature, 2008
- Familial Multiple Myeloma Associated with Disorders of Chronic Inflammation: First Report from Turkey, 2008
- Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group, 2008
- Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders, 2008
- High CD95 expression of BAL lymphocytes predicts chronic course in patients with sarcoidosis, 2007
- International uniform response criteria for multiple myeloma, 2006
- Expression of IFITM1 in chronic myeloid leukemia patients, 2005
- Filgrastim-Mobilized Peripheral Blood Progenitor Cells Versus Bone Marrow Transplantation For Treating Leukemia: 3-Year Results From The EBMT Randomized Trial, 2005
- HLA A B C DR haplotypes linkeage and frequencies observed inAnkara University Turkey a report from Tran, 2005
- Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft-versus-host disease, 2004
- Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow, 2003
- Differences between graft product and donor side effects following bone marrow or stem cell donation, 2003
- CD41+ and CD42+ hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation, 2001
- Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914), 2001
- The effect of G-CSF on lymphocyte subsets and CD34 cells in allogeneic stem cell transplantation, 2001
- Frequent demonstration of human herpesvirus 8 (HHV-8) in bone marrow biopsy samples from Turkish patients with multiple myeloma (MM), 2001
- Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation, 2001
- CD41 and CD42 hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation, 2001
- Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia, 2001
- Soluble adhesion molecules (sICAM-1, sL-Selectin, sE-Selectin, sCD44) in healthy allogenic peripheral stem-cell donors primed with recombinant G-CSF, 2000
- Thrombopoietic Cytokines in Patients with Iron Deficiency Anemia with or without Thrombocytosis, 2000
- Chronic graft-versus-host disease complicated by membranous glomerulonephritis, 1999
- The impact of the CD34 cell dose on engraftment in allogeneic peripheral blood stem cell transplantation, 1999
- Incidence of Tuberculosis after bone marrow transplantation in a single center from Turkey, 1998
- Randomised unicenter trial for comparison of three regimens inde novo adult acute nonlymphoblastic leukaemia, 1998
- HLA DR2: A predictive marker in response to cyclosporine therapy in aplastic anemia, 1997
- Hepatitis B virus infection in allogeneic bone marrow transplantation, 1997
- A RAPID DRUG SENSITIVITY ASSAY FOR NEOPLASMATIC CELLS, 1988
- Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide, 2024
- External Valıdatıon Of Three Exıstıng Early Myeloma Relapse Scores (By Ebmt, Cıbmtr, And Gımema) In A Sıngle Center Shows Major Dıfferences, 2023
- Validation of the EBMT Multiple Myeloma Early Relapse Score within Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study, 2024
- Health-Related Quality of Life (HRQoL) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplantation and Treated with Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Vs. Vrd Alone: Results from the Imroz Study, 2024
- Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial, 2024
- Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM), 2024
- Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM), 2024
- Real-World Experience with Isatuximab in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Iona-MM Second Interim Analysis,
- Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd), 2024
- Analysis of Beta-catenin Mutations in Acute Myeloid Leukemia., 2017
- Otoimmün Hemolitik Anemi ve T-LGL Birlikteliği Nadir Bir Olgu, 2023
- Hemofili A ve Multipl Miyelom Tanılı Hastada Otolog Periferik Kök Hücre Mobilizasyonu: Olgu Sunumu, 2023
- Kök hücre toplamada Plerixafor' un yeri: Kemoterapisiz de olur mu?, 2023
- Myelofibroziste allojenik hematopoetik kök hücre nakli sonuçları: tek merkez deneyimi, 2023
- Siklofosfamid ile Mobilizasyonunun Multipl Miyelom Hastalarında Nakil Sonuçlarına Etkileri, 2023
- MULTİPL MİYELOMDA KILLER IMMUNOGLOBULIN-LIKERESEPTÖRLERİ (KIR) VE LİGANDLARI İLE HLA- GRUP C1 VEC2’NİN SIKLIĞI, 2017
- KIR2DS4’ÜN MİYELOM PLAZMA HÜCRELERİNE KARŞIOTOLOG VEYA KORDON KANI DOĞAL ÖLDÜRÜCÜ HÜCREARACILIKLI TOKSİSİTEDE ROLÜ, 2018
- İndüksiyon Mu Hazırlama Rejimi Mi Daha Önemli? İndüksiyon Sonrası Kalıntı Hastalığın Saptanamaması Bir Prognostik Gösterge Olabilir, 2018
- Multipl miyelomda Killer Immunoglobulin like Reseptörleri (KIR) ve ligandları ile HLA- Grup C1 ve C2'nin sıklığı, 2017
- Decreased Multiple Myeloma Viability of Malignant Plasma Cells by Inhibition of Werner Helicase, 2017
- OTOLOG PERİFERİK KÖK HÜCRE NAKLİNDE KÖK HÜCRESAKLANMA SÜRESİ ENGRAFMAN SÜRESİNİ ETKİLER Mİ?, 2017
- ALLOJENEİK HEMATOPOETİK KÖK HÜCRE NAKLİ SONRASI AKUT MYELOİD LÖSEMİ NÜKSÜNÜN YÖNETİMİ VE PROGNOZU, 2018
- YENİ TANI KLL HASTALARINDA TANI SIRASINDAKİ CD49DEKSPRESYONUNUN HASTALIĞA OZGU BAŞKA PARAMETRELERLEİLİŞKİSİ, 2019
- Evaluating response to treatment in patients with EMD, 2022
- Post-authorization safety of lenalidomide+dexamethasone in patients with multiple myeloma in Turkey, 2022
- Current status & updates in the management of AL amyloidosis, 2022
- The potential of studying circulating plasma cells in multiple myeloma, 2022
- Updates of ongoing EMN studies, 2022
- Quadruplet therapy with and without autoHSCT in NDMM, 2022
- Extramedullary Dısease, 2022
- Plasma Cell Disorders subcommittee Project Presentations, 2022
- Multipl Miyelom ve yeni nesil tedavi seçenekleri, 2022
- Extramedullary myeloma, 2022
- Special Lectures on Extramedullary Disease, 2022
- Selecting frontline treatments strategies & monitoring patients with multiple myeloma, 2022
- Preventing and managing post-transplant complications in multiple myeloma, 2022
- Risk assessment & transplant decisions in multiple myeloma, 2022
- The value of MRD as a prognostic tool in myeloma, 2022
- An insight into familial myeloma, 2022
- Multiple myeloma, 2022
- Plasma cell disorders subcommittee projects presentation, 2022
- A Focus on Multiple Myeloma, 2022
- Contemporary Management of AL Amyloidosis, 2022
- MRD to drive therapy, 2022
- Efficacy and outcome of modern standard treatment vs. ASCT in newly diagnosed multiple myeloma patients, 2022
- EBMT scoring system for early relapse after auto-HCT in MM Patients, 2022
- Pomalidomide (POM), bortezomib (BORT), and dexamethasone (DEX) after 1 prior line of therapy in relapsed or refractory multiple myeloma (RRMM): a safety subanalysis of the phase 3 OPTIMISMM trial, 2022
- Prophylactic defibrotide is effective for acute graft versus host disease as well as sinusoidal obstructive syndrome, 2022
- Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia: A single center experience, 2022
- Graft Versus Host Hastalığı Profilaksisinde ATG Ve Post CY Kullanımının Nakil Sonuçlarına Etkisi: Tek Merkez Deneyimi, 2022
- İkinci Allojeneik Kök Hücre Nakli: Gerçek Yaşam Verisi, 2022
- Amniyon Sıvısının, VPA İle Ekspande Hematopoietik Kök Hücre Nakli Sonrası Engrafmana Etkisinin İn Vivo Araştırılması, 2022
- OKHN Sonrası İlk 12 Ayda Nüksü Belirlemede Gımema Ve CIBMTR Skorlama Yaklaşımlarının Bağımsız Hasta Grubunda Validasyonu, 2022
- Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19), 2022
- Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study, 2022
- Autologous Peripheral Blood Stem Cell Mobilisation Techniques, Stem Cell Yields and Practice Variation-By-Country in Patients with Myeloma Undergoing First Autologous Stem Cell Transplants in EBMT Centres between 2012 and 2021, 2022
- Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies, 2022
- 64th ASH Annual Meeting & Exposition, 2022
- MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma, 2022
- The efficacy and safety of second allogeneic hematopoietic stem cell transplantation, 2022
- Ibrutınıb As A Promısıng Treatment For Waldenström Macroglobulınemıa, 2022
- Carfılzomıb, Lenalıdomıde, Dexamethasone Followed By A Second Auto-Hct Is An Effectıve Strategy In Fırst Relapse Multıple Myeloma: A Study Of The Chronıc Malıgnancıes Workıng Party Of EBMT, 2022
- Daratumumab Plus Bortezomıb And Dexamethasone Versus Bortezomıb And Dexamethasone Alone In Patıents Wıth Prevıously Treated Multıple Myeloma: Overall Survıval Results From The Phase 3 Castor Trıal, 2022
- Response And Vaccınatıon Status Or Lack Of Immunoparesıs Are Assocıated Wıth Better Outcome Followıng Covıd-19 Infectıon Among Patıents Dıagnosed Wıth Multıple Myeloma: A Sıngle Center Experıence On 110 Patıents, 2022
- Pomalıdomıde, Bortezomıb, And Dexamethasone In Lenalıdomıde–Pretreated Multıple Myeloma: A Subanalysıs Of Optımısmm By Fraılty, 2022
- Ex Vivo Epigenetic Modification with Valproic Acid (VPA) Plus Nicotinamide (NAM) Results in Expansion of Umbilical Cord Blood Hematopoietic Progenitors Leading to Faster Engraftment and Chimerism in In Vivo Mouse Xenograft Model, 2022
- Phase 3 Study of Belantamab Mafodotin with Pomalidomide (Pom) + Dexamethasone (Dex) vs Bortezomib + Pom/Dex in Relapsed/Refractory Myeloma, 2022
- Daratumumab(DARA)+Bortezomib/Cyclophosphamide/Dexamethasone (D-VCd) in Newly Diagnosed AL Amyloidosis: 18-month Landmark Analysis of ANDROMEDA, 2022
- Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone Alone in Patients With Previously Treated Multiple Myeloma: Overall Survival Results From the Phase 3 CASTOR Trial, 2022
- An Early Post-Transplant Relapse Predıctıon Score In Multıple Myeloma Patıents: A Large Cohort Study From Chronıc Malıgnancıes Workıng Party Of EBMT, 2022
- Pomalidomide, bortezomib, and dexamethasone in lenalidomide-pretreated multiple myeloma: A subanalysis of OPTIMISMM by frailty, 2022
- EX VIVO EXPANSION OF HUMAN UMBILICAL CORD BLOOD HEMATOPOIETIC STEM CELLS (HSCS) WITH VALPROIC ACID (VPA) OR NEUROTROPHIC FACTOR (NTF), 2017
- Comparision of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Center Institution Experience, 2018
- KIR 2DS4 May Influence Autologous and Cord Blood(CB) Natural Killer (NK)Cell Mediated in Vitro Cytotoxicity Against Freshly Isolated Human Bone Marrow Myeloma Plasma Cells and Cell Lines, 2018
- The Outcome of Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation for Isolated CD4(+) T-cell Deficiency with Interleukin-2 Inducible T-cell Kinase (ITK) Gene Defect, 2018
- Carfilzomib ve Pomalidomid Etkinliğinin Retrospektif Değerlendirilmesi: Ankara Üniversitesi Deneyimi, 2017
- Ankara Üniversitesi Tıp Fakültesi Multiple Myelom Elotuzumab ve İmmünmodulatuar İlaç Tedavi Deneyimi, 2017
- İmmun Trombositopenide (İTP) Yenilikler Işığında Klinik Retrospektif Değerlendirme: Tek Merkez Deneyimi, 2017
- Clonal Plasma Cell Detection by High Sensitive Flow Cytometry in Aphaeresis Product is Poor Prognostıc and not Increased by Use of Plerixafor Alone, 2019
- Evaluating peritransplant albumin decline as a predictor of acute graft versus host disease, 2017
- Large unstained cell percentage as a predictor of efficacious peripheral stem cell mobilization in autologous stem cell transplantation, 2017
- Therapeutic Thrombocytapheresis: Higher Platelet Counts Should Matter, 2016
- Heparin Enhances CD34 Content of Stem Cells Collected Following G-CSF +/- Chemotherapy, 2017
- A prospective analysis on the frequency and predictive value of minimal residual disease assessment by flow cytometry and PET-CT imaging among myeloma patients on/off maintenance, 2018
- A Preliminary Analysis of Inherited Immune Checkpoint Control in Multiple Myeloma: Relative Frequency of Inhibitory or Activating Type Killer Immunoglobulin like Receptors and Their Cognate Ligands HLA-C1 and -C2, 2017
- Residual Clonal Plasma Cells Detected by Flow Cytometry at 10-4 Level within Autologous Stem Cell Grafts is Associated with Significantly Less Overall Survival, 2018
- Multipl Miyelom Olgularında Otolog Kök Hücre Naklinde Yüksek Doz Melfelana Bortezomib Eklenmesinin Tek Merkez Sonuçları, 2019
- Plerixafor, Periferik Kök Hücre Ürününde Akım Sitometri İle Saptanabilen Klonal Plazma Hücre Kontaminasyonunu Etkiler Mi?, 2019
- The Effect Of Predıcted Indırectly Recognızable Hla Epıtopes Presented By Hla-Class Iı Molecules On 1 Antıgen/Alelle Mısmatched Unrelated Hsct: A Sıngle Center Experıence, 2019
- Can Nelarabıne Rescue The Graft After Allogeneıc Hematopoıetıc Stem Cell Transplantatıon In T-All ?, 2019
- Negative Impact of High LDH at Diagnosis on OS, But Not PFS, Can Be Overcome by Autologous Stem Cell Transplantation, 2019
- Haplotypes rich in activating killer-cell immnuglobulin-like receptor genes are associated with delay on age of myeloma onset, 2021
- Postinduction minimal residual disease (MRD) within stem cell graft (gMRD) correlates with marrow MRD (mMRD) and progression free survival (PFS) following autologous stem cell transplantation, 2021
- Allogeneic hematopoietic stem cell transplantation for primary myelofibrosis: A single-center experience, 2020
- A real-world single-center retrospective study on efficacy and safety of pegylated interferon alpha-2a in patients with myeloproliferative neoplasm, 2020
- Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?, 2019
- Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation, 2019
- Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis, 2020
- KIR Genotype and KIR Ligand Phenotypes That Improve the in Vitro Cord Blood or Autologous NK Cell Mediated Cytotoxicity Against Myeloma Marrow Plasma Cells, 2020
- Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow, 2020
- Age is Not an Important Factor for Autologous Peripheral Hematopoietic Stem Cell Mobilization and Collection in Patients with Multiple Myeloma, 2018
- A retrospective single center experience with the generic of lenalidomide Rivelime (R) compared with original patented drug Revlimid (R), 2019
- Is post-transplant albumin a predictor of early transplant complications?, 2018
- Ruxolitinib in steroid refractory GVHD treatment: single center experience, 2018
- Fit Elderly Patients with aggressive lymphoma do not need dose reduction of conditioning regimen, 2018
- Impact of Hepatitis B Core Antibody Seopositivity on the Liver Function Tests after Autologous Hematopoietic Stem Cell Transplantation For Multiple Myeloma, 2018
- Results Of A Sıngle Center Experıence: An Attempt To Augment Condıtıonıng Regımen In Fırst Autologous Stem Cell Transplantatıon, 2019
- Is mobilization with chemotherapy effect response in the multiple myeloma?, 2019
- Haploidentical stem cell transplantation may be an option for hematological malignancies in urgent conditions, 2019
- Treatment Of Thrombocytopenıa After Allogeneıc Stem Cell Transplantatıonwıth Eltrombopag, 2020
- Flamsa-Based Hıgh-Dose Sequentıal Condıtıonıng Regımen Followed By Allogeneıc Hematopoıetıc Stem Cell Transplantatıon (Allo-Hsct): Is It Effectıveın Patıents Wıth Prımary Refractory Or Relapsed Acute Leukemıa?, 2020
- The Influence Of Antı-Thymocyte Globulın (Atg) On The Outcomes Of Patıents Wıth Aml W/Wo Measurable Resıdual Dısease (Mrd) At The Tıme Of Unrelated Donor Transplantatıon, 2020
- Role Of Chımerısm And Flow-Cytometrıc Monıtorıng Of Measurable Resıdualdısease (Mrd) After Allogeneıc Hematopoıetıc Stem Cell Transplantatıon (Allohsct) In Predıctıng Relapse In Acute Myeloıd Leukemıa (AML), 2020
- Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data, 2019
- Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?, 2019
- Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis, 2019
- Next Generation Sequencing May be Helpful in Designing Novel Combinations Among Heavily Pretreated Myeloma Patients, Refractory to All Available Approved Anti-Myeloma Drugs, 2019
- Safety of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Patients with Multiple Myeloma Presenting with Extramedullary Disease during the COVID-19 Pandemic, 2021
- KILLER IMMUNOGLOBULIN LIKE HAPLOTYPE BB IS OBSERVED MORE FREQUENTLY AMONG MYELOMA CASES COMPARED TO HEALTHY CONTROLS, 2021
- CAN ELTROMBOPAG TREAT THE THROMBCYTOPENIA AFTER STEM CELL TRANSPLANTATION, 2019
- PRE-TRANSPLANT HEMOGLOBIN AND SERUM CREATININE LEVELS CORRELATE WITH PROGRESSION FREE SURVIVAL IN MYELOMA PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION, 2019
- LEUKAPHERESIS REDUCES 4-WEEK MORTALITY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH HYPERLEUKOCYTOSIS - A RETROSPECTIVE STUDY FROM A TERTIARY CENTER, 2019
- CAN AUTOLOGOUS STEM CELL TRANSPLANTATIONABROGATE THE POOR PROGNOSIS ASSOCIATED WITH HIGH LDH?, 2019
- POSTTRANSPLANT LENFOSİTOZ ÖNEMLİ BİR PARAMETRE MİDİR?, 2019
- AKUT MİYELOİD LÖSEMİDE NAKİL ÖNCESİ MİNİMAL KALINTI HASTALIK DİĞER RİSK FAKTÖRLERİNDEN DAHA ÖNEMLİ MİDİR?, 2019
- Yurt İçi Ve Yurt Dışı Gönüllü Akaraba Dışı Vericilerde HLA Özdeşlik Durumu : 10/10 >9/10 Mu Yoksa En Büyük HLADPB1 Mi?, 2021
- ALLOJENİK HEMATOPOİETİK KÖK HÜCRE NAKLİ YAPILAN ALL HASTALARINDA CMV ENFEKSİYONUNUN NAKİL SONUÇLARINA ETKİLERİ, 2018
- Allojeneik Hematopoetik Kök Hücre Nakli Sonrası Akut Myeloid Lösemi Nüksünün Yönetimi ve Prognozu, 2018
- NGS TÜM SEÇENEKLERİ TÜKETMİŞ NÜKS VE DİRENÇLİ MM HASTALARINDA ENDİKASYON DIŞI TEDAVİ OLUŞTURMADA REHBERLİK EDEBİLİR Mİ?, 2019
- Evaluation of chemokine reseptor 4 expression by 68Ga Pentixafor PET/CT in patients with multiple myeloma, 2018
- Large Unstained Cell Percentage as a Predictor of Efficacious Peripheral Stem Cell Mobilization, 2017
- A biosimilar G-CSF filgrastim is as effective as a reference drug, however, it is not as cost effective as it supposed to be, 2017
- Engrafmanın Erken Belirteci: Büyük Boyanmamış Hücreler, 2017
- Evaluation of chemocine reseptor 4 expression by 68Ga pentixafor PET/CT in patients with multiple myeloma, 2018
- Multiple myeloma - Frontline therapy, 2021
- The management of R/R multiple myeloma patients, 2021
- DM6-1 Response in Multiple Myeloma, 2021
- Post-Induction Undetectable Minimal Residual Disease at 10-5 Sensitivity Level within Marrow and/or Stem Cell Graft Overrides Cytogenetic High Risk, 2021
- Ülkemiz Ailesel Miyelom Olgularında Saptanan Varyantlar :RAG2, CBL, APC ve PTCH1 Genleri, 2021
- Hastalık biyolojisinde güncel gelişmeler, 2021
- Kordon Kanı Kök Hücre ve Natural Killer Hücre Ekspansiyonu, 2021
- Plasma cell disorders subcommittee projects presentation, 2021
- IMID’LERDE ARTAN GÜÇ: POMALIDOMID, 2021
- Treatment with BiTEs: Is it the new standard for penta-refractory patients?, 2021
- Response in Multiple Myeloma, 2021
- Therapy of elderly patients, 2021
- Multiple Miyelom, 2021
- Scoring system for Auto-HCT: feasibility in MM patients, 2021
- Prediction of Early Death and Severe Infections during Novel Agent-Based Induction Therapy in Newly-Diagnosed Multiple Myeloma: An Intergroup Analysis from the German Speaking Myeloma Multicenter Group, the Dutch–Belgian Cooperative Trial Group for Hematology Oncology Foundation and the European Myeloma Network, 2021